SCOTUS Declines Second Look at Chinese Vitamin C Antitrust Case

The US Supreme Court declined Monday to revive antitrust litigation over an alleged price-fixing scheme by Chinese exporters of vitamin C, a few years after the justices took a skeptical view of claims that the companies were just complying with Chinese law.

The high court said it won’t review a ruling by the US Court of Appeals for the Second Circuit, which has twice thrown out a $148 million verdict against the manufacturers, Hebei Welcome Pharmaceutical Co. and parent North China Pharmaceutical Group Corp.

The justices tentatively reinstated the judgment in 2018, saying the Second Circuit bent over too far ...